(Q43608668)

25 November 2017

Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: a functional study (English)

1 reference

25 November 2017

1 reference

1

1 reference

25 November 2017

A Fasoli

2

1 reference

25 November 2017

F Botta

3

1 reference

25 November 2017

E Testa

4

1 reference

25 November 2017

P Romagnoli

5

1 reference

25 November 2017

P Ceppa

6

1 reference

25 November 2017

R Testa

7

1 reference

25 November 2017

1 April 2001

1 reference

Journal of Gastroenterology and Hepatology

25 November 2017

1 reference

25 November 2017

16

1 reference

25 November 2017

4

1 reference

25 November 2017

399-405

1 reference

Natural history of hepatitis C.

25 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Patterns of progression: unpredictability and risk of decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Interferon treatment of chronic hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Cirrhosis: diagnosis by liver surface analysis with high-frequency ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Proposed abdominal sonographic staging to predict severity of liver diseases: analysis with peritoneoscopy and histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Progressive liver functional impairment is associated with an increase in AST/ALT ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Predictors of one-year pretransplant survival in patients with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Histologic determinants of monoethylglycinexylidide formation in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

The effect of age on plasma MEGX concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

The effect of liver disease and food on plasma MEGX concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2001.02463.X

10.1046/J.1440-1746.2001.02463.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference